Clinical Trials Logo

Clinical Trial Summary

The study is designed to compare the steady-state pharmacokinetics of Prograf (Brand) and the two most disparate generic formulations (Generic Hi and Generic Lo) in a fully replicated, 3-way cross-over study in stable kidney (n=36) and liver transplant (n=36) subjects.


Clinical Trial Description

To identify the most disparate tacrolimus generic drug formulations among those currently approved in the United States. We will conduct systematic dissolution testing of the brand and all currently approved tacrolimus drug formulations using the FDA-recommended dissolution method. We propose to test and compare the 1mg capsule strength (3 production lots/ manufacturer). In addition, we will compare the different formulations in terms of potency, purity and other quality attributes. This work will be carried out in the GMP-compliant facilities of The University of Iowa Pharmaceuticals and the University of Colorado. Based on these studies the two most disparate generic tacrolimus formulations (Generic Hi and Generic Lo) will be selected and compared with the Brand (PrografR, Astellas, Deerfield, IL) in the clinical trial.

This is an open label, prospective, multicenter, randomized, replicate, six-period, three-sequence cross-over study to compare the steady state pharmacokinetics of PrografR to Generic Hi to Generic Lo in stable kidney and liver transplant subjects. The PK assessor will be blinded to the assigned treatment sequence and formulation. The person analyzing the levels and analyzing the results will be blinded to formulation sequence. Each subject will be randomized to one of the three sequences where Generic Hi and Generic Lo represent the two generics and B the brand, Prograf. The blood samples will be collected at C0 (before morning dose) and then 20, 40, 60(1hr), 80, 100, 120(2hr), 140, 160, 180(3hr) minutes, 4, 5, 6, 8 and 12 hour after dosing with each formulation. Adherence will be monitored by patient diary, pill counts, and MEMS cap. Safety and efficacy parameters will be monitored weekly.

This study will be carried out in full compliance with the rules of Good Clinical Practice (GCP) including development of an electronic database and monitoring plan.

Resulting pharmacokinetic parameters will be analyzed by a variety of pharmacokinetic tests such as narrower acceptance intervals, individual and scaled average bioequivalence was well as population pharmacokinetics. ;


Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01889758
Study type Interventional
Source University of Cincinnati
Contact
Status Completed
Phase Phase 4
Start date June 2013
Completion date January 2016

See also
  Status Clinical Trial Phase
Completed NCT01336296 - Evaluate Effects and Safety of Pre-load Myfortic® in Transplant Patients Phase 4
Recruiting NCT01150487 - Paired Marrow Aspirations to Assess Assays in Sensitized Renal Allograft Recipients N/A
Recruiting NCT05938712 - The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients Phase 2
Completed NCT00217100 - A Multivitamin Comparison Study in Kidney Transplant Recipients. Phase 3
Active, not recruiting NCT00199667 - Concentration Controlled Versus Fixed Dose of MMF in Kidney Transplant Recipients Phase 4
Terminated NCT01517984 - Immune Monitoring and CNI Withdrawal in Low Risk Recipients of Kidney Transplantation Phase 2
Recruiting NCT04642833 - Prostate Cancer in Renal Transplants Recipients
Not yet recruiting NCT05293704 - An Open Study on the Preventive Effect of Early Mizoribine Conversion on BKV Nephropathy in Renal Transplant Recipients Phase 4
Completed NCT02555566 - Role of Epoxyeicosatrienoic Acids in Chronic Allograft Nephropathy - The TRANSPLANT-EETs Study N/A
Completed NCT01782586 - Validation of Gene Expression Markers of Renal Allograft Functional Decline
Enrolling by invitation NCT02042963 - KoreaN Cohort Study for Outcome in Patients With Kidney Transplantation (KNOW-KT) N/A
Not yet recruiting NCT05702398 - Pilot Trial of Supplemental Vitamin A and Nicotinamide Early Phase 1
Active, not recruiting NCT05425498 - The Effects of Physical Activity Behavior Change in Kidney Transplant Recipients N/A
Terminated NCT02268201 - A Study to Evaluate the Efficacy and Safety in Kidney Transplant Recipients When Changed From Cyclosporine to Tacrolimus Prolonged-release Capsule or Tacrolimus Capsule Phase 4
Active, not recruiting NCT03979365 - Envarsus XR Compared to Immediate Release Tacrolimus Phase 4
Recruiting NCT04965935 - Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients Phase 3
Recruiting NCT04444843 - Risk Factors of Chinese Kidney Transplant Recipients DSA Based on MPA Immunosuppressive Regimen Phase 4
Completed NCT02392312 - Observational Study to Evaluate the Safety and Efficacy of ATG-F on Kidney Transplant Recipients
Completed NCT02639949 - Measuring and Improving Medication Adherence in Kidney Transplant Patients N/A
Withdrawn NCT02058875 - Cardiovascular Risk Following Conversion to Full Dose Myfortic® and Neoral® Two-hour Post Level Monitoring Phase 4